| May 17 |
Virios Therapeutics announces proposed public offering of common stock
|
| May 17 |
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
|
| May 13 |
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q1 2024 Earnings Call Transcript
|
| May 13 |
VIRI: Results for Phase 2 Long COVID Trial Expected in 2H24…
|
| May 12 |
Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript
|
| May 9 |
Virios Therapeutics GAAP EPS of -$0.07 misses by $0.03
|
| May 9 |
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
|
